E-DRUG: Lancet article supports generic ARVs (2)
-----------------------------------------
I cannot agree more with KR Frost. Unfortunately for a lot of African countries there are no strong regulatory authorities and good laboratories to varify the quality of ARVs that they will be getting from, for example Aspen, an African company. What is needed is for the MCC in South Africa to make sure the Aspen does not send poor quality products to to other African countries.
Big Pharma in in the past have always maintained that what they did in a country was dictated by laws and regulation in that country. Those days are gone. Poor countries in Africa, especially those that do not have laboratories need to be encouraged to set up ARV therapeutic effectiveness mechanisms. People living with HIV need to be involved by being ecouraged to feedback.
Norman
Member of WHO African Technical Network on ARVs
nznyazema@yahoo.com